Abaloparatide for osteoporosis

• Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of male osteoporosis: a systematic review and Bayesian network meta-analysis
• Male Osteoporosis: A Comprehensive Review of Treatment Approaches in Modern Pharmacotherapy and Traditional Chinese Medicine Interventions
• The Chronobiology of Hormone Administration: "Doctor, what time should I take my medication?"
• Clinical efficacy of osteoporosis treatments
• Probability of Achieving Bone Mineral Density Treatment Targets with Abaloparatide and Teriparatide
• An oral robotic pill reliably and safely delivers teriparatide with high bioavailability in healthy volunteers: A phase 1 study
• Role of Anabolic Anti-Osteoporosis Therapy in Diabetes Subjects
• Osteoporosis therapy - Update 2025, Part 2: Sequential osteoporosis therapy

see Osteoporosis treatment.

(TymlosTM):

a recombinant DNA copy of the entire human parathyroid hormone.

Rx: 80 micrograms SQ daily. Lifetime treatment limit of all parathyroid analogs total: 2 years

Abaloparatide increases bone formation for treating established osteoporosis.

Initial treatment with abaloparatide may result in greater vertebral fracture reduction compared with alendronate in postmenopausal women with osteoporosis ¹⁾.

Sequential therapy using ABL/alendronate (ALN) may be cost effective compared with generic ALN monotherapy in US men aged ≥ 50 years at high fracture risk, especially in those aged ≥ 60 years. Unbranded teriparatide (TPTD)/ALN and no treatment were dominated interventions (less QALY, more costs) compared with ABL/ALN or ALN monotherapy ²⁾

Have not yet been studied in the chronic glucocorticoid population ³⁾.